Protara Therapeutics reported a net loss of $61.1 million for the nine months ended September 30, 2026, compared to a $40.1 million loss in the prior year, driven primarily by a significant increase in research and development expenses. As of September 30, 2026, the company maintained $127.1 million in cash, cash equivalents, and marketable debt securities to fund its clinical pipeline, including TARA-002 and IV Choline Chloride.
Protara Therapeutics reported third quarter 2026 financial results and provided a clinical pipeline update, including the expected completion of enrollment for its TARA-002 registrational cohort in NMIBC by year-end. The company also announced an $8.75 million asset purchase agreement with Novex Innovations for manufacturing-related assets and reported a cash position of $143 million, sufficient to fund operations into 2028.
“Protara continues to deliver across our late-stage portfolio, advancing each of our programs toward its next key clinical and regulatory milestone. This steady progress positions us to close out the year with strong momentum and sets the stage for an impactful 2027.”
Jesse Shefferman, Chief Executive Officer at Protara Therapeutics
“TARA-002 has the potential to be a preferred treatment option for patients with non-muscle invasive bladder cancer (NMIBC), and we are on track to complete enrollment of the BCG-Unresponsive registrational cohort by year-end, a key step toward bringing this therapy to patients.”
Jesse Shefferman, Chief Executive Officer at Protara Therapeutics